M Peghin1,2, V Monforte3,4, M T Martin-Gomez5, I Ruiz-Camps1,2, C Berastegui3,4, B Saez3,4, J Riera6, J Solé7, J Gavaldá1,2, A Roman3,4. 1. Department of Infectious Diseases, Hospital Universitari de la Vall d'Hebron, Barcelona, Spain. 2. Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. 3. Department of Pulmonology and Lung Transplant Unit, Hospital Universitari de la Vall d'Hebron, Barcelona, Spain. 4. Ciber Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. 5. Department of Microbiology, Hospital Universitari de la Vall d'Hebron, Barcelona, Spain. 6. Department of Intensive Care Unit, Hospital Universitari de la Vall d'Hebron, Barcelona, Spain. 7. Department of Thoracic Surgery, Hospital Universitari de la Vall d'Hebron, Barcelona, Spain.
Abstract
OBJECTIVES: Our aim was to assess the impact of positive cultures for non-Aspergillus molds on the risk of progression to invasive fungal infection (IFI), and the effect of prophylactic nebulized liposomal amphotericin B (n-LAB) on these pathogens. METHODS: This was an observational study (2003-2013) including lung transplant recipients (LTR) receiving lifetime n-LAB prophylaxis, in whom non-Aspergillus molds were isolated on respiratory culture before and after transplantation (minimum 1-year follow-up). RESULTS: We studied 412 patients, with a mean postoperative follow-up of 2.56 years (interquartile range 1.01-4.65). Pre- and post-transplantation respiratory samples were frequently positive for non-Aspergillus molds (11.9% and 16.9% of LTR respectively). Post transplantation, 10 (2.42%) patients developed non-Aspergillus mold infection (4 Scedosporium species, 4 Purpureocillium species, 1 Penicillium species, and 1 Scopulariopsis species); 5 (1.21%) had IFI, with 60% IFI-related mortality. Non-Aspergillus molds with intrinsic amphotericin B (AB) resistance were more commonly isolated in bronchoscopy samples than AB-variably sensitive or AB-sensitive molds (54.5% vs. 25%, P = 0.04) and were associated with a higher risk of infection (56.3% vs. 1.3%%, P < 0.01). CONCLUSIONS: In LTR undergoing n-LAB prophylaxis, pre- and post-transplantation isolation of non-Aspergillus molds is frequent, but IFI incidence (1.21%) is low. Purpureocillium is an emerging mold. AB-resistant non-Aspergillus species were found more often in bronchoscopy samples and were associated with a higher risk of infection.
OBJECTIVES: Our aim was to assess the impact of positive cultures for non-Aspergillus molds on the risk of progression to invasive fungal infection (IFI), and the effect of prophylactic nebulized liposomal amphotericin B (n-LAB) on these pathogens. METHODS: This was an observational study (2003-2013) including lung transplant recipients (LTR) receiving lifetime n-LAB prophylaxis, in whom non-Aspergillus molds were isolated on respiratory culture before and after transplantation (minimum 1-year follow-up). RESULTS: We studied 412 patients, with a mean postoperative follow-up of 2.56 years (interquartile range 1.01-4.65). Pre- and post-transplantation respiratory samples were frequently positive for non-Aspergillus molds (11.9% and 16.9% of LTR respectively). Post transplantation, 10 (2.42%) patients developed non-Aspergillus mold infection (4 Scedosporium species, 4 Purpureocillium species, 1 Penicillium species, and 1 Scopulariopsis species); 5 (1.21%) had IFI, with 60% IFI-related mortality. Non-Aspergillus molds with intrinsic amphotericin B (AB) resistance were more commonly isolated in bronchoscopy samples than AB-variably sensitive or AB-sensitive molds (54.5% vs. 25%, P = 0.04) and were associated with a higher risk of infection (56.3% vs. 1.3%%, P < 0.01). CONCLUSIONS: In LTR undergoing n-LAB prophylaxis, pre- and post-transplantation isolation of non-Aspergillus molds is frequent, but IFI incidence (1.21%) is low. Purpureocillium is an emerging mold. AB-resistant non-Aspergillus species were found more often in bronchoscopy samples and were associated with a higher risk of infection.
Authors: C Staerck; P Vandeputte; A Gastebois; A Calenda; S Giraud; N Papon; J P Bouchara; M J J Fleury Journal: Mycopathologia Date: 2017-06-21 Impact factor: 2.574
Authors: Jonathan P Huggins; Robert Pease; Kelly Stanly; Adrienne Workman; John Reynolds; Barbara D Alexander Journal: Antimicrob Agents Chemother Date: 2022-05-04 Impact factor: 5.938
Authors: Eszter Judit Tóth; Éva Boros; Alexandra Hoffmann; Csilla Szebenyi; Mónika Homa; Gábor Nagy; Csaba Vágvölgyi; István Nagy; Tamás Papp Journal: Front Immunol Date: 2017-10-18 Impact factor: 7.561